Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
Regulatory update – GSK announces regulatory submission for albiglutide in Europe
GSK today announced the submission of a Marketing Authorisation Application (MAA) for albiglutide, with the proprietary name EPERZAN, to the European Medicines Agency (EMA).
Read more -
ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1
ViiV Healthcare presents 24-week interim results from Phase III SAILING study at the 20th Conference on Retroviruses and Opportunistic Infections (CROI)
Read more -
ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children
Agreement brings the number of voluntary licences granted by ViiV Healthcare to 14.
Read more -
GSK and Theravance announce FDA acceptance of New Drug Application (NDA) submission in the US for ANORO ELLIPTATM for COPD
GSK and Theravance, Inc. today announced that the New Drug Application (NDA) for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chroni...
Read more -
ViiV Healthcare announces FDA priority review designation for dolutegravir as a potential treatment for HIV infection
ViiV Healthcare today announced that the FDA has granted a priority review designation to dolutegravir submitted for the treatment of HIV infection.
Read more -
Regulatory update – GSK announces European submission for MEK monotherapy and BRAF/MEK combination therapy in metastatic melanoma
GlaxoSmithKline (GSK) plc today announced submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for trametinib (MEK) as monotherapy and in c...
Read more -
Results announcement for the fourth quarter 2012
GSK delivers 2012 core EPS of 112.7p and returns £6.3bn to shareholders
Read more -
GSK increases stake in its publicly-listed Consumer Healthcare subsidiary in India to 72.5 per cent
GSK announced today that, pursuant to the voluntary open offer undertaken by its subsidiary, GlaxoSmithKline Pte. Ltd, GSK has successfully increased its stake in GlaxoSmithKlin...
Read more -
GSK announces support for AllTrials campaign for clinical data transparency
Campaign calls for full disclosure of clinical trial results and clinical study reports to help drive scientific understanding.
Read more -
GlaxoSmithKline starts Phase III study to test combined BRAF/MEK inhibition in patients with BRAF positive melanoma following surgery
GSK today announced the start of COMBI-AD, a Phase III study evaluating the combination of dabrafenib, its BRAF inhibitor and trametinib, its MEK inhibitor as adjuvant therapy ...
Read more -
GSK response to news article in The Guardian on UK legal proceedings related to Avandia (rosiglitazone)
Responding to a news article in The Guardian this morning on UK legal proceedings related to our type 2 diabetes medicine Avandia (rosiglitazone), we would like to make the foll...
Read more -
GSK and Biological E. announce joint venture to develop combination vaccine for India and other developing countries
GlaxoSmithKline (GSK) and Biological E Limited (Biological E.), a leading Indian vaccines company, today announced an agreement to form a 50/50 joint venture (JV) for the early ...
Read more -
GSK appoints Hans Wijers to its Board as a Non-Executive Director
GlaxoSmithKline plc (LSE: GSK) today announced the appointment of Hans Wijers to its Board as a Non-Executive Director, effective 1st April 2013.
Read more -
GSK signs up to UK Government’s Public Health Responsibility Deal
Pledge to reduce the sugar and calorie content of Lucozade Energy and Ribena products.
Read more -
Regulatory update – GSK announces submission of albiglutide BLA to the US FDA for the treatment of type 2 diabetes
GlaxoSmithKline (GSK) plc today announced a regulatory submission to the US Food and Drug Administration (US FDA) for albiglutide, an investigational once-weekly treatment for a...
Read more -
GSK and Theravance announce regulatory submission for ANORO™ (UMEC/VI) in Europe
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application in the European Union for the investigational once-daily...
Read more -
GSK and Theravance announce regulatory submission for UMEC/VI (LAMA/LABA) in the US
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application in the US for the investigational once-daily LAMA/LABA c...
Read more -
FDA Approves GlaxoSmithKline’s four-strain seasonal influenza vaccine for use in the US
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved FLUARIX® QUADRIVALENT (Influenza Virus Vaccine) for the immunisation of ch...
Read more -
Results from five phase III studies presented for GSK’s two candidate quadrivalent influenza vaccines
GSK today announced that results from five Phase III studies investigating its two candidate quadrivalent influenza vaccines were presented at the Influenza Vaccines for the Wor...
Read more -
GSK announces further initiatives to advance openness and collaboration to help tackle global health challenges
Speaking at a meeting hosted by the Wellcome Trust in London today, GSK CEO Sir Andrew Witty will outline new steps to build on the encouraging signs of progress resulting from ...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
